Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 2/20 | 0.36 |
| ▸ | CA9 | Q16790 | 2/20 | 0.36 |
| ▸ | CA4 | P22748 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | GABRP | O00591 | 1/20 | 0.35 |
| ▸ | GABRD | O14764 | 1/20 | 0.35 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.35 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.35 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.35 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.35 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.35 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.35 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.35 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.35 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3508924 | 0.87 | ALDH1A1 (0.47) | KMT2AALDH1A1CA2CA9HPGD | |
| SCHEMBL29363509 | 0.87 | ALDH1A1 (0.47) | KMT2AALDH1A1CA2CA9HPGD | |
| SCHEMBL3645280 | 0.82 | ALDH1A1 (0.38) | KMT2AALDH1A1MEN1GAASMN1; SMN2 | |
| SCHEMBL19384608 | 0.82 | MDM4 (0.49) | KMT2AALDH1A1MEN1GAAHPGD | |
| SCHEMBL23363317 | 0.81 | GRM5 (0.37) | KMT2AALDH1A1MEN1CA2CA9 | |
| SCHEMBL26098394 | 0.81 | ALDH1A1 (0.37) | KMT2AALDH1A1MEN1GAAHPGD | |
| SCHEMBL12133550 | 0.80 | LCK (0.46) | KMT2A | |
| SCHEMBL15940490 | 0.79 | KMT2A (0.40) | KMT2AALDH1A1MEN1GAASMN1; SMN2 | |
| SCHEMBL3707609 | 0.79 | MAPT (0.47) | KMT2AALDH1A1MEN1SMN1; SMN2HPGD | |
| SCHEMBL1538399 | 0.77 | KMT2A (0.35) | KMT2AALDH1A1MEN1GAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11091484-B2 | Tricyclic heterocycles as BET protein inhibitors | INCYTE CORPORATION (US) | 2021-08-17 | — | — | US | disclosed |
| US-10442803-B2 | Tricyclic heterocycles as bet protein inhibitors | INCYTE CORPORATION (US) | 2019-10-15 | — | — | US | disclosed |
| US-20180002334-A1 | TRICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS | INCYTE CORPORATION | 2018-01-04 | — | — | US | disclosed |
| US-9777003-B2 | Tricyclic heterocycles as bet protein inhibitors | INCYTE CORPORATION (US) | 2017-10-03 | — | — | US | disclosed |
| US-20160168148-A1 | TRICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS | INCYTE CORPORATION | 2016-06-16 | — | — | US | disclosed |
| US-9309246-B2 | Tricyclic heterocycles as BET protein inhibitors | INCYTE CORPORATION (US) | 2016-04-12 | — | — | US | disclosed |
| WO-2015095492-A1 | TRICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS | INCYTE CORPORATION (US) | 2015-06-25 | — | — | WO | disclosed |
| US-20150175604-A1 | TRICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS | INCYTE CORPORATION (US) | 2015-06-25 | — | — | US | disclosed |
| EP-2391623-A1 | INHIBITORS OF AKT ACTIVITY | Merck Sharp & Dohme Corp. (US) | 2011-12-07 | — | — | EP | disclosed |
| WO-2010088177-A1 | INHIBITORS OF AKT ACTIVITY | MERCK SHARP & DOHME CORP. (US) | 2010-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180002334-A1 | TRICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS | BRD1, BRD3, BRD2 | KMT2A 742/4885ALDH1A1 4703/4885MEN1 2156/4885 |
| US-10442803-B2 | Tricyclic heterocycles as bet protein inhibitors | BRD1, BRD3, BRD2 | KMT2A 742/4885ALDH1A1 4703/4885MEN1 2156/4885 |
| US-20160168148-A1 | TRICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS | BRD1, BRD3, BRD2 | KMT2A 742/4885ALDH1A1 4703/4885MEN1 2156/4885 |
| US-11091484-B2 | Tricyclic heterocycles as BET protein inhibitors | BRD1, BRD3, BRD2 | KMT2A 742/4885ALDH1A1 4703/4885MEN1 2156/4885 |
| US-20150175604-A1 | TRICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS | BRD1, BRD3, BRD2 | KMT2A 742/4885ALDH1A1 4703/4885MEN1 2156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.